Accessibility Menu
Talphera logo

Talphera(NASDAQ) TLPH

Market Cap$67.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-99%
5 Year-94%
1 Year+195%
1 Month+25%
$1.31
+0.39%
+0.01Today
Talphera last closing stock price
MetricPriceDate
Last closeUSD 1.312026-07-29
Talphera stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.55%USD 1.292026-07-22
1 month+24.76%USD 1.052026-06-29
3 month+44.11%USD 0.912026-04-30
Year to date+14.91%USD 1.142025-12-31
1 year+194.65%USD 0.442025-07-29
3 year+32.32%USD 0.992023-07-28
5 year-94.45%USD 23.602021-07-30
Since inception-98.57%USD 91.002011-02-11

Talphera Financials at a Glance

Market Cap

$67.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.00K

Net Income (TTM)

-$14.25M

EPS (TTM)

-$0.30

P/E Ratio

-4.35

Dividend

$0.00

Beta (Volatility)

0.84 (Low)

Price

$1.31

Volume

132,940.597

Open

$1.29

Previous Close

$1.31

Daily Range

$1.26 - $1.35

52-Week Range

$0.39 - $1.57

Estimated Earnings Date

Aug 13, 2026

TLPH News

Foolcom-Featured.png

Talphera Cuts Expenses 14 Percent

Motley Fool Markets TeamAug 14, 2025
featured-earnings-leadership-highlights.png

Talphera Cuts Costs and Speeds Trial

Motley Fool Markets TeamAug 14, 2025
penny

2 Penny Stocks That Could Make You Filthy Rich

George Budwell, PhDMar 9, 2021
$1 bill folded into an arrow pointing down

Why AcelRx Pharmaceuticals Stock Is Sinking Today

Keith SpeightsJan 20, 2021
biotech down

Here's Why AcelRx Pharmaceuticals Fell as Much as 14% Today

Maxx ChatskoMay 9, 2019
Growth2

3 Stocks Peter Lynch Would Love

George Budwell, PhDApr 29, 2019
Test tube and question mark

Why AcelRx Pharmaceuticals Stock Is Sinking Today

Keith SpeightsMar 8, 2019
red buy

3 Top Small-Cap Stocks to Buy Right Now

George Budwell, PhDMar 4, 2019
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Talphera

Talphera develops medicines for hospital settings, helping doctors manage complex treatments. Its main product, Niyad, aims to prevent blood clots during kidney therapy. The company focuses on therapies for patients needing close medical supervision.

What’s in the Medicine Cabinet?

  • Niyad (Lead Product): Anticoagulant for kidney therapy circuits; no revenue yet; targets hospitals and clinics.
  • LTX-608: Anti-inflammatory and antiviral drug candidate; no revenue; aimed at severe illness treatment in hospitals.
  • Fedsyra: Pre-filled ephedrine syringe for blood pressure support; no revenue; under review for discontinuation.
  • PFS-02: Pre-filled phenylephrine syringe for blood pressure; no revenue; also under review for discontinuation.
  • DSUVIA (Divested): Pain medication; commercial sales ended in 2023; Talphera is eligible for royalties from U.S. Department of Defense sales only, but has not received any due to absence of DoD sales as of March 2026.

Growth Spurts and Strategic Moves

  • Acquired Lowell Therapeutics in 2022, adding Niyad and LTX-608 to its pipeline.
  • Divested DSUVIA to Alora Pharmaceuticals in April 2023, shifting focus to hospital therapies.
  • Sold future DSUVIA-related payments to XOMA for $8 million in January 2024.
  • Raised capital through private placements in 2024 and 2025 to fund operations.
  • Ongoing clinical trial for Niyad, with completion expected in 2026.

What Makes Talphera Stand Out?

Talphera focuses on therapies for hospital use, targeting gaps in current treatment options. Its lead product, Niyad, could become the first FDA-approved anticoagulant for kidney therapy circuits in the U.S. The company relies on contract manufacturers and holds international patent applications for its main products.

Five Things You Need to Know

  • Revenue was $1,000 in Q3 2025, down 99.1% from Q3 2023.
  • Net loss was $14.3 million in 2025, up 10% from 2024.
  • Cash and investments were $20.4 million at December 31, 2025.
  • All revenue comes from the U.S; no international sales reported.

Bottom Line

Talphera has shifted from pain management to hospital-focused therapies, with Niyad as its main asset. The company faces funding challenges but continues to develop specialized treatments for critical care settings.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

12

CEO

Vincent J. Angotti, MBA

Website

talphera.com

Headquarters

San Mateo, CA 94404, US

TLPH Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-1451600.00%

Net Income Margin

-1425300.00%

Return on Equity

-92.98%

Return on Capital

-57.30%

Return on Assets

-47.27%

Earnings Yield

-22.99%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$67.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

51.90M

Volume

132.94K

Avg. Volume

276.70K

Financials (TTM)

Gross Profit

$1.00K

Operating Income

-$14.52M

EBITDA

-$14.25M

Operating Cash Flow

-$11.29M

Capital Expenditure

$0.00

Free Cash Flow

-$11.29M

Cash & ST Invst.

$21.11M

Total Debt

$0.00

Talphera Performance Analysis

Talphera annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 651,000N/A
20242024-12-31USD 0N/A
20252025-12-31USD 28,000N/A
Talphera sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-100.0%
Q32025-09-30N/A
Q42025-12-31-100.0%
Q12026-03-31N/A
Talphera annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 5.72N/A
20232023-12-31USD -1.29N/A
20242024-12-31USD -0.50-61.0%
20252025-12-31USD -0.34-33.0%
Talphera sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-10.0%
Q42025-12-3119.2%
Q12026-03-3132.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$67.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.67M

N/A

Employees

12

N/A

Net Income

-$2.56M

+1.4%

EBITDA

-$2.56M

-1122.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$21.11M

+291.8%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

N/A

Return on Assets

-47.27%

N/A

Return on Invested Capital

-55.55%

N/A

Free Cash Flow

-$3.40M

+2.0%

Operating Cash Flow

-$3.40M

+2.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MIRAMIRA Pharmaceuticals, Inc.
$0.84+0.21%
NTRBNutriband Inc.
$2.88-2.54%
PIIIP3 Health Partners Inc.
$10.50-0.19%
SCYXSCYNEXIS, Inc.
$3.77+3.43%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About TLPH

What is the current price of Talphera?

Talphera is trading at $1.31 per share.

What is the 52-week range for Talphera?

Over the past 52 weeks, Talphera has traded between $0.39 and $1.57.

How much debt does Talphera have?

As of the most recent reporting period, Talphera reported total debt of $6.50M.

How much cash does Talphera have on hand?

Talphera reported $3.82M in cash and cash equivalents in its most recent financial results.

What is Talphera’s dividend yield?

Talphera does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services